BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Clinical Trials

NouvNeu001 Marks Milestone in iRegene's c Trial with Successful First Patient Dosing

It is reported that the multicenter, open-label clinical trial (Phase I/II) is meticulously crafted to systematically evaluate the safety, tolerability, an...

February 06, 2024 | News

Pliant Therapeutics Reports Positive Results in Bexotegrast Trial for Liver Fibrosis

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety conce...

February 05, 2024 | News

Sirius Therapeutics Begins Phase 1 Trial for Long-Acting Factor XI siRNA Anticoagulant

"This study is based on in vivo studies that have demonstrated a nearly 100% reduction in FXI levels for up to 6 months without bleeding events a...

February 04, 2024 | News

SoniVie Completes Enrollment in REDUCED-1 Pilot Study for TIVUS™ Renal Denervation

SoniVie, an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive disor...

February 01, 2024 | News

Taiwan's Anbogen Secures $12.5M in Series A for Precision Oncology

The lead investor is China Development Industrial Bank (CDIB), with significant contributions from Taian Venture Capital, Maxpro and the National Developme...

February 01, 2024 | News

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 Diabetes (T2D), announced that the U...

January 31, 2024 | News

Vertex's Breakthrough VX-548: Transforming Pain Management with Rapid Relief and Safety, A New Era in Acute Pain Solutions

Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from ...

January 31, 2024 | News

Peijia Medical Completes Enrollment for TaurusTrio™ Aortic Regurgitation Trial

The multi-center trial utilized the TaurusTrioTM TAVR system to treat pure AR in 116 patients across 13 hospitals within China and is design...

January 30, 2024 | News

Nanoform Achieves Key Milestone in Clinical Trials for Enhanced Enzalutamide

These were from a relative bioavailability study of nanocrystalline-enabled enzalutamide (nanoenzalutamide) tablet formulation, an alternative to the amorp...

January 29, 2024 | News

Ascletis Initiates Phase III Trial of ASC40 (Denifanstat) for Acne Treatment with First Patient Dosed

This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and e...

January 25, 2024 | News

Caliway Receives Initial Approval for CBL-514 Phase 3 Fat Reduction Study

"We are all delighted to see CBL-514 showing its potential to become the new, promising, non-invasive fat reduction treatment in the previous Pha...

January 24, 2024 | News

Sagimet Biosciences Reports Positive Results in Phase 2b Trial of Denifanstat for F2/F3 NASH

- Primary efficacy endpoints: NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in ...

January 24, 2024 | News

EMA grants Orphan Drug Designation to GC Biopharma's Sanfilippo Syndrome (Type A) Treatment

GC1130A has previously achieved notable milestones by securing both Rare Pediatric Disease designation (RPDD) and Orphan Drug Designation (ODD) from the U....

January 24, 2024 | News

AIM ImmunoTech Initiates Phase 1b/2 Trial for Ampligen® and AstraZeneca's Imfinzi® in Late-Stage Pancreatic Cancer

AIM ImmunoTech Inc. announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM&rs...

January 23, 2024 | News

Stay Connected